Targets › PTDSS1
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Jan 2027.
Catalyzes a base-exchange reaction in which the polar head group of phosphatidylethanolamine (PE) or phosphatidylcholine (PC) is replaced by L-serine. Catalyzes mainly the conversion of phosphatidylcholine. (UniProt, P48651)
Open in Phaseline: the race on PTDSS1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Maryland, Baltimore | Bavituximab Anti-phosphatidylserine monoclonal antibody that binds to phosphatidylserine after binding | PTDSS1 | Phase 2 | Squamous Cell Carcinoma | Jan 2027 |
Squamous Cell Carcinoma (1)
antibody (1)
University of Maryland, Baltimore (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.